Reconciling recommendations for ethical sharing of biomarker results with Alzheimer's disease research participants: A systematic review and qualitative synthesis
- 5 November 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (1) , 46-57
Abstract
Background: The shift toward a biological definition of Alzheimer's disease (AD) has led to increased use of biomarkers (e.g., amyloid, tau, APOE genotype) in research settings. As return of biomarker results becomes more common in AD research, understanding how participants perceive and make decisions about receiving individual research results is essential for ethical trial design and informed consent practices. Objective: (1) To map and appraise the landscape of qualitative and mixed-methods research focused on perspectives of AD research community members related to biomarker result sharing in AD research settings; and (2) to synthesize findings on decisional needs of research participants considering whether to receive individual biomarker or genetic risk information. Methods: We searched PubMed and EMBASE for qualitative and mixed-methods studies published between January 2012 and January 2025. Eligibility criteria included empirical studies reporting qualitative data on experiences, attitudes, or decision-making processes related to receiving AD biomarker or genetic results in research contexts. Results: Of 3269 records screened, 42 records were assessed for eligibility and 8 met inclusion criteria and were included in our final analysis. Participants emphasized empowerment through research participation and desire for knowledge related to research results. Across studies, decisional needs, characterized as “aspects of decision-making” clustered around four domains: (1) clarity of biomarker meaning and limitations, (2) emotional readiness and support, (3) social consequences of disclosure, and (4) alignment with personal values and future planning. Conclusions: Findings can inform the development of ethically grounded protocols for returning individual research results in preclinical AD trials.Keywords
Funding Information
- Alzheimer's Association (AARG-22-974462)
This publication has 31 references indexed in Scilit:
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trialAlzheimer's & Dementia, 2022
- Ethical Considerations in Communicating Alzheimer's Disease Neuroimaging Biomarker Test Results to Symptomatic IndividualsNeurotherapeutics, 2021
- Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive ImpairmentJAMA Neurology, 2020
- Stakeholders’ Views on Early Diagnosis for Alzheimer’s Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group StudyJournal of Bioethical Inquiry, 2019
- Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosureAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2018
- Amnestic MCI Patients’ Perspectives toward Disclosure of Amyloid PET Results in a Research ContextNeuroethics, 2017
- Patient and caregiver reactions to clinical amyloid imagingAlzheimer's & Dementia, 2017
- Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research ResultsJAMA Neurology, 2015
- Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011